Trial Profile
Phase II Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2016
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Apr 2010 New trial record